CLINICAL DEVELOPMENT AND OPTION AGREEMENTClinical Development and Option Agreement • August 4th, 2016 • Medgenics, Inc. • Biological products, (no disgnostic substances) • New York
This Clinical Development and Option Agreement (this “Agreement”) is made and entered into effective as of this 6th day of June, 2016 (the “CDOA Effective Date”), by and between Kyowa Hakko Kirin Co., Ltd. (“KHK”), having a place of business at 1-6-1, Otemachi, Chiyoda-ku, Tokyo 100-8185, Japan, and Medgenics, Inc. (“Medgenics”), having an address at 435 Devon Park Drive, Building 700, Wayne, PA 19087, U.S.A. Each of KHK and Medgenics may be referred to herein individually as a “Party” and together as the “Parties.”
